Morgan Stanley raised the firm’s price target on Disc Medicine (IRON) to $120 from $115 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech’s outperformance in 2026 as commercial names transition from “capital consumers to producers” and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Jefferies sees ‘overreaction’ to article on Disc Medicine’s EPP approvability
- Disc Medicine (IRON): Constructive FDA Dialogue and APOLLO Progress Support Buy Rating Despite Volatility
- BMO Capital says call with Disc management clarifies active FDA dialogue
- TD Cowen says Disc Medicine remains confident, bito timeline under CNPV intact
- Disc Medicine falls -14.3%